Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Menopausal HRT and breast cancer: 1 million already at risk

Pearl Toh
09 Sep 2019

Use of menopausal hormone therapy (MHT) was associated with a significantly increased risk of invasive breast cancer, which became progressively greater with longer duration of use, a meta-analysis of worldwide prospective epidemiological studies has shown.

The risk was elevated even with 1–4 years of MHT use and persisted beyond 10 years after stopping MHT, in particular for those who had used MHT for 5 years or more.

“If the associations are largely causal, MHT use in western countries has already caused about 1 million breast cancers, out of a total of about 20 million since 1990,” highlighted the researchers.

Type, duration, frequency: It all matters

Among the 108,647 breast cancer cases in postmenopausal women (mean age 65 years) included in the meta-analysis, 55,575 (51 percent) had used MHT. The therapy was used for an average of 10 years among current users and 7 years among past users. The mean age of starting MHT was 50 years. [Lancet 2019;doi:10.1016/S0140-6736(19)31709-X]

All types of MHT were found to be associated with excess risks of breast cancer, except topical vaginal oestrogen which limits systemic exposure. Specifically, the risk was greater for oestrogen-progestagen vs oestrogen-only preparations, in particular when the progestagen was used daily rather than intermittently (adjusted risk ratios [RRs], 2.30 vs 1.93; p<0.0001 for heterogeneity).

The excess risks were definite even with just 1–4 years of use (RRs, 1.60 and 1.17 for oestrogen-progestagen and oestrogen-only preparations, respectively), and became progressively greater with longer use: RRs, 2.08 and 1.33, respectively for 5–14 years of use and 1.58 and 2.51, respectively for 15 years of use. There was little excess risk associated with less than 1 year of MHT use (RRs, 1.08, 95 percent confidence interval [CI], 0.86–1.35 for oestrogen only and 1.20, 95 percent CI, 1.01–1.43 for for oestrogen progestogen).      

Consequently, 5 years of MHT use, starting at age 50 years would increase the 20-year breast cancer incidence by “one in every 50 users of oestrogen plus daily progestagen preparations; one in every 70 users of oestrogen plus intermittent progestagen preparations; and one in every 200 users of oestrogen-only preparations,” stated the researchers.

For any given preparation, there was a greater association between 5–14 years of MHT use and oestrogen receptor (ER)-positive tumours than ER-negative tumours (RRs, 1.45 vs 1.25 for oestrogen only and 2.44 vs 1.42 for oestrogen progestagen).

In addition, the excess risk associated with 5–14 years of MHT use was similar regardless of when the women started using MHT after age 40 (RRs, 1.26–1.33 for oestrogen only and 1.97–2.22 for oestrogen progestogen), while the risk was attenuated by starting MHT after the age of 60, in particular for oestrogen-only preparations (RR, 1.08, 95 percent Ci, 0.90–1.31).     

The excess risk with MHT use was also attenuated with adiposity, meaning women who were obese were less likely to have breast cancer than nonobese women. However, the researchers noted that higher BMI itself was already associated with an increased incidence of ER-positive breast cancer in postmenopausal women who never used MHT.

“For women who are obese, use of oestrogen-only MHT adds little to their already elevated breast cancer risk, suggesting that this addition of an exogenous oestrogen adds relatively little to the adiposity-associated oestrogenic stimulation of their breast tissue,” explained the researchers.

“Both obesity and MHT are risk factors for postmenopausal breast cancer, but it appears that the effects are not additive,” added Dr Joanne Kotsopoulos from University of Toronto, Toronto, Canada in a commentary. [Lancet 2019;doi:10.1016/S0140-6736(19)31901-4]

Among past users of MHT, breast cancer risks remained elevated even after more than a decade of stopping MHT. Again, the excess risks were greater with longer MHT use previously.   

When to start and for how long?

These findings bear major clinical relevance, in terms of the extent of the absolute risks both during and after MHT use, as well as public health relevance with regard to the vast number of women who were previously and currently exposed, the researchers pointed out. 

“For women of average weight in developed countries 5 years of use, starting at age 50 years, would cause an appreciable increase in the probability of developing breast cancer at ages 50–69 years,” said the researchers. 

“About half the excess would be during the first 5 years of current use of MHT, and half would be during the next 15 years of past use.”

Clinicians should consider the risks and benefits of starting MHT for each woman in managing menopausal symptoms, taking into consideration the severity of symptoms, contraindications for MHT, BMI, and patient preference, urged Kotsopoulos.

“For likely candidates, MHT (preferably oestrogen alone) should be initiated around the time of natural menopause and ideally limited to 5 years of use,” she advised.

 

 

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 4 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 5 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.